VolitionRx Announces New Chief Financial Officer

NAMUR, Belgium, July 1, 2014 /PRNewswire/ -- VolitionRx Limited (OTCQB: VNRX), a life sciences company, today announces the appointment of a new Chief Financial Officer (CFO), Mike O'Connell. Mr. O'Connell will take on this key role as VolitionRx works towards securing a listing on a senior US stock exchange.

Mike O'Connell is presently the CEO of Isosceles, a business accounting and HR consultancy which he founded in 2001 to provide high-quality accounting services to entrepreneurial companies of all sizes. He has held CFO and Financial Director (FD) roles at a number of private to public companies with multimillion dollar turnovers, including the role of CFO at InsightSoftware.com and FD at Pacific Group PLC. Mr. O'Connell was educated at Imperial College London before qualifying as a Chartered Accountant with Ernst and Young in London.

Cameron Reynolds, CEO of VolitionRx, said, "We are sorry to lose Malcolm Lewin; he has been an important member of the team since our inception. Mike O'Connell brings with him significant expertise in senior financial roles, in both UK and US companies."

"I'm excited to be joining VolitionRx as CFO," added Mike O'Connell. "It's a fantastic company with such a promising technology, and I look forward to working with the team as we work towards an uplist to a senior US stock exchange."

About VolitionRx

VolitionRx is a life sciences company focused on developing blood-based diagnostic tests for different types of cancer. The tests are based on the science of Nucleosomics which is the practice of identifying and measuring nucleosomes in the bloodstream – an indication that cancer is present.

VolitionRx's goal is to make the tests as common and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. VolitionRx's research and development activities are currently centred in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the US and ultimately, worldwide.

Visit VolitionRx's website (www.volitionrx.com) or connect with us on Twitter, LinkedIn, Facebook or YouTube.

Media Contacts:

Charlotte Reynolds, VolitionRx
Telephone: +44 (0) 795 217 7498
Email: charlotte.reynolds@volitionrx.com

Eleanor Stuart, Racepoint Global
Telephone: +44 (0) 208 811 2124
Email: eleanor.stuart@racepointglobal.com

Investor Contact:

Scott Powell, VolitionRx
Telephone: +1 917 721 9480
Email: s.powell@volitionrx.com

Safe Harbor Statement

Statements in this press release may be "forward-looking statements". Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "optimizing," "potential," "goal," and similar expressions, as they relate to the Company, its business or management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in the Company's filings with the Securities and Exchange Commission.

SOURCE VolitionRx Ltd